Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

NCT01109615 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Stopped Lacking effect of treatment

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Pemetrexed
DRUG: Gemcitabine

Sponsor

Vejle Hospital